Dr. Partin’s laboratories are focused on development and testing of new and existing methods for predicting the aggressiveness of prostate cancers so that rational treatment decisions can be made by both patients and physicians. The laboratories have investigated many new serum tests, some of which are soon to become available for the diagnosis of prostate cancer as well as basics science investigation of new proteins, which may help in detection, and staging of prostate cancer.
Clinical Trial Keywords:
Sundi D, Wang V, Pierorazio PM, Han M, Partin AW, Tran PT, Ross AE, Bivalacqua TJ. "Identification of men with the highest risk of early disease recurrence after radical prostatectomy." Prostate. 2014 Jan 22. doi: 10.1002/pros.22780.
Ball MW, Mullins JK, Epstein JI, Partin AW, Walsh PC. "Re: detailed analysis of patients with metastasis to the prostatic anterior fat pad lymph nodes: a multi-institutional study: I. Y. Kim, p. K. Modi, e. Sadimin, y.-S. Ha, j. H. Kim, d. Skarecky, d. Y. Cha, C. O. Wambi, y.-C. Ou, B. Yuh, s. Park, e. Llukani, d. M. Albala, T. Wilson, T. Ahlering, k. Badani, h. Ahn, d. I. Lee, m. May, w.-J. Kim and d. H. Lee j urol 2013;190:527-534." J Urol. 2014 Feb;191(2):559-61. doi: 10.1016/j.juro.2013.07.103.
Sundi D, Wang VM, Pierorazio PM, Han M, Bivalacqua TJ, Ball MW, Antonarakis ES, Partin AW, Schaeffer EM, Ross AE. "Very-high-risk localized prostate cancer: definition and outcomes." Prostate Cancer Prostatic Dis. 2014 Mar;17(1):57-63. doi: 10.1038/pcan.2013.46.
Inoue LY, Trock BJ, Partin AW, Carter HB, Etzioni R. "Modeling grade progression in an active surveillance study." Stat Med. 2014 Mar 15;33(6):930-9. doi: 10.1002/sim.6003.
Loeb S, Assimos D, Chancellor MB, Nickel JC, Brawer MK, Kern AJ, Partin AW. "Best of the 2013 AUA Annual Meeting: Highlights From the 2013 American Urological Association Meeting, May 4-8, 2013, San Diego, CA." Rev Urol. 2013;15(2):72-81. Review.